Evidence map›Paper›PMID 39433508›Full record

ArticleJournal of biomedical research2024

Study of the mass balance, biotransformation, and safety of [

Shuaishuai Wang, Wen Lin, Bilal Ahmed, Tianqi Zhong, Jun Zhao, Lijun Xie, Hao Feng, Juan Chen, Chen Zhang, Peng Yan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant 
Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shuaishuai WangMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Wen LinMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Bilal AhmedMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Tianqi ZhongPhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Jun ZhaoPhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Lijun XiePhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Hao FengValue Pharmaceutical Services Co., Ltd., Nanjing, Jiangsu 211806, China.
Juan ChenPhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Chen ZhangNuclear Medicine Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Peng YanNuclear Medicine Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Shirui ZhengInnovent Biologics Co., Ltd., Shanghai 201107, China.
Lingge ChengInnovent Biologics Co., Ltd., Shanghai 201107, China.
Yipeng ChengInnovent Biologics Co., Ltd., Shanghai 201107, China.
Bei ZhuPhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Feng HanMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Lulu ZhangMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, International Joint Laboratory for Drug Target of Critical Illnesses, Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Chen ZhouPhase Ⅰ Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IBI351, a synthetic compound, exerts its anti-tumor effects by specifically, covalently, and irreversibly modifying the 12th cysteine residue of KRAS G12C. However, the pharmacokinetic profile of IBI351 in humans has not yet been reported. The current study aimed to investigate the pharmacokinetics and safety of IBI351 in healthy Chinese male subjects. A single oral dose of 600 mg combined with 150 μCi [

Indexed as

IBI351KRAS G12C inhibitormass balancemetabolismpharmacokineticsradiolabel study

Identifiers

PMID39433508
PMCPMC12329412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.